Fosun Pharma Subsidiary’s Cyclophosphamide Injection Application Accepted by Chinese Regulator

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application submitted by its subsidiary Jisimei (Wuhan) Pharmaceutical for Cyclophosphamide Injection, a chemical drug independently developed by the group. The oncology-focused injectable is indicated for a wide range of cancers, including multiple lymphoma subtypes, multiple myeloma, various leukemias and solid tumors such as ovarian adenocarcinoma, retinoblastoma and breast carcinoma, and Fosun has invested about RMB7.4 million in its R&D to date, underscoring the group’s continued push to expand its oncology portfolio and strengthen its position in China’s cancer treatment market.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based pharmaceutical group engaged in the research, development, manufacturing and commercialization of chemical drugs and other medical products, with a focus on serving domestic and overseas healthcare markets through a network of subsidiaries.

Average Trading Volume: 3,861,331

Technical Sentiment Signal: Sell

Current Market Cap: HK$74.73B

Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.